San Francisco Study Looks At Individuals Who Seek Out HIV Post-Exposure Prevention

June 30, 1998

GENEVA, Switzerland--In the first study of its kind, a team of San Francisco AIDS specialists has conducted a systematic review of individuals who seek out Post-Exposure Prevention (PEP) treatment following a possible exposure to HIV. The researchers--from the University of California San Francisco and the San Francisco Department of Public Health--looked at giving potent anti-HIV medications and intensive counseling to people possibly exposed to HIV by a sexual activity or intravenous drug use.

James O. Kahn, MD, associate professor of medicine in the UCSF AIDS Program at San Francisco General Hospital, presented PEP study findings here today (June 30) at the 12th World AIDS Conference.

The ongoing study focuses on the conditions that cause people to come to a PEP clinic, the decisions they make about their options, and how they fare. The idea of giving anti-retroviral drugs to someone possibly exposed to HIV is not new. These drugs have been prescribed for the past 10 years to health care workers who suffer accidental needle sticks, with the thought that HIV infection could be stopped before it has a chance to spread in the body. "Our study is the first to describe a number of fundamental aspects of PEP," said Kahn. "We know some doctors are prescribing anti-retroviral therapy for HIV exposure to their patients, but they are not collecting the vital data needed to understand the implications of having PEP available to all individuals in the community."

"For example, we need to know what type of exposures cause people to seek information about PEP, which individuals choose to take medications, how patients adhere to the month-long treatment, what side- effects develop, and how people's risk-taking behavior changes after taking PEP and receiving our intensive counseling," Kahn said.

The study began in November 1997 and is being conducted at three sites in San Francisco. To date, 151 patients have enrolled in the study. "This field is in its infancy. No one is 100 percent certain that anti-retrovirals given within 72 hours of exposure to HIV will prevent infection, but there is considerable evidence that suggests that it will," said co-investigator Jeffrey Martin, MD, MPH, UCSF assistant professor of medicine, and epidemiology and biostatistics, who will present further findings on July 1 regarding PEP treatment.

"This study is not testing whether PEP works per se, but it is looking at who is interested in receiving medications We feel it is essential to understand the demand for the drugs and some of the consequences in prescribing them," he said. When patients with possible exposure to HIV show up at one of the three study-sponsored clinics in San Francisco, they are tested for HIV, counseled about their risk, and advised on the pros and cons of the PEP drugs. The most common regimen is two drugs given for four weeks along with risk reduction counseling. The patients are tested at four weeks, again at six months, and at one year for the development of HIV infection.

Whenever possible the counselors try to have the exposed person bring in his or her partner for testing so that the risk of HIV exposure can be known for sure. "There was some concern that having PEP as an option might discourage safe sex practices," said Martin. "So far, however, we have only found a handful who are repeatedly coming in. And the fact that they are coming in gives us access to these high-risk takers who are not heeding other safe sex messages."

Since the beginning of the study last November, findings include:

Study principal investigator is Thomas Coates, PhD, UCSF professor of medicine, epidemiology and biostatistics and director of the UCSF AIDS Research Institute (UCSF ARI). Co-investigators are Michelle Roland, MD, and Margaret Chesney, PhD, both of UCSF; and Joshua Bamberger, MD, MPH, and Mitchell Katz, MD, director, both of the San Francisco DPH.

The study is supported by the National Institutes of Allergy and Infectious Disease of the National Institutes of Health, Glaxo-Wellcome, Bristol Myers Squibb, Agouron Corporation, and Chiron Corporation. The UCSF ARI is an institute without walls that encompasses all UCSF AIDS programs under a single umbrella. The ARI includes a dozen research institutes, a wide range of clinical, behavioral science, and policy programs, and nearly 1,000 investigators.
-end-


University of California - San Francisco

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.